Unconventional Vaccines: Immunization with Antildiotype Antibody Against Viral Diseases'

Unconventional Vaccines: Immunization with Antildiotype Antibody Against Viral Diseases'

[CANCER RESEARCH (SUPPL.)45, 4689s-4690s, September1985] Unconventional Vaccines: Immunization with Antildiotype Antibody against Viral Diseases' H. Koprowski TheWistarinstitute,Philadelphia,Pennsylvania19104 Theconceptofantiidiotypevaccinesrelatestothegeneration forproductionofAb@inrabbitsdidnotneutralizethevirusbut of immuneresponseto an antigen(virus,bacteria,parasites)by did bind to viral glycoproteins.The Ab@elicitedin mice after immunizationofthehostwithan immunoglobulinthatdefinesa immunizationwiththe Ab@antibodynotonlyboundto viral specificregionon the anti-pathogenantibodymoleculeand in glycoproteinbutalsoneutralizedthevirus(7). In the nonviral turn engendersan antibodythat mimicsin its functionsuch an antigenfieldAb@elicitedbyimmunizationwitha-Id monoclonal anti-pathogenantibody.Thetheoreticalbasisfor thisconcept antibodyagainstanti-fructosanantibodydifferin their reactivity canbe foundinthe immunenetworktheoryfirstproposedby patternsto anti-fructosanantibodiesproducedafter immuniza Jerne(1)inwhichtheinterplayofantigen-bindingsitesonanti tionwithbacteriallevan(10). bodymoleculesandhostimmunocytesleadsto theexistenceof severaltypes of antibodiesdevelopedsequentiallyinthe same Advantagesofa-Id ViralVaccines individualimmunizedagainsta givenantigen(see “Glossary―). The aim of immunizationwithanti-idiotypeantibodyis to The existenceofa-Id antibodiesdirectedto cross-reactive producean antibody(Ab3)reactingwith the antigenin such a idiotypessharedby anti-viralantibodiesofdifferentfinespecific waythatit willprotectthehostfromthedisease.Thishasbeen itiesmaymakeit moredifficultfora virusto escapeimmune achievedin severalviralinfections.As shownin Table1 immu surveillance by antigenic variation. A virus may evade immune nizationof micewith a-Id2led to the developmentofvirus defensesifitexistsinnatureinmanyantigenicvariantformsas reactiveantibodiesinseveralviralsystems.Inthecaseof reo maybethecaseinthehumanT-cellleukemiavirusfamilyorifit virus(2)andSendai(3)it wasalsopossibletogeneratevirus acquires antigenic changes in the course of infection within the specificcytotoxicT-ceIIsafterimmunizationofmicewith mono sameindividualhost; the latter is particularlyimportantin the clonala-Idantibodies.Inthecaseof hepatitisBvirus,theAb@ caseof twootherretroviruses,visna(11)andequineinfectious engenderedbyimmunizationwitha-Id boundto a peptide(4) anemia(12). that may represent part of an a determinantwhich induces Theotherobviousadvantageina-Idvaccinesistheabsence commonId(5). of the viralantigen.Thiscircumventstheoftentortuousand Mice immunizedwith a-Id to Sendai monoclonalantibody sometimesunpredictablesearchfortracesoflivenoninactivated resistedchallengewiththehomologousvirus(3).Withrabies(6) virusina productthatisultimatelyusedforhumanconsumption. andpolioviruses(7)thelevelofneutralizingAb@wasapparently Forinstanceinthecaseofhighlyinfectiousandhighlycontagious too low to protectagainstchallengebuta boosterinjectionwith Venezuelanequineencephalomyelitisvirustheproductionofviral a nonimmunizingdoseof vaccine(toolowfor immunizationof vaccinesthat were completelyinnocuousfor intracerebrallyin naivemice)enabledthesemiceto resistviralchallenge(6).In jectedguineapigsendedincausingdiseaseinhumansimmu thecaseofhepatitisBvirusoneinjectionofa-Iddidnotengender nizedwithsucha vaccine(13—15).Contrastthiswiththe a-Id hepatitisB-specificantibodybutmultipleinjectionsora booster vaccineinwhichviralantigenis in no way involved(16). inoculationwitheither122—137peptideorinactivatedhepatitis Furtheradvantagesofa-Id vaccinesmaybe theirabilityto B virusresultedin an immuneresponse(8). induceimmuneresponsesinhostswhoareincapableofrespond In generala-Id antibodiesthatengenderedantigen-reactiveing directlyto an antigen.For exampleinfantswho do not Ab3werecross-reactiveforidiotopescommontomanyantibody respondwelltovaccinationwithStreptococcuspneumoniaemay preparationsgeneratedindifferentanimalspecies. beableto developimmunitybyimmunizationwitha-Id.Animal The dosageof a-Id seemsto be of importanceinorderto studieshaveshownthattreatmentatbirthwithmonoclonala-Id produceantigen-reactiveAbe.Rabies-reactingAb@wasinduced antibodiesto levan-bindingproteinsfollowedby a boosterinoc afterimmunizationofmicewith2.5 or 1.25 @gofa-Idforoneof ulationwiththe samea-Id antibodygeneratesalevan-specific the threeimmunizinginjectionsbutnot with dosesequalor antibodyresponse(10). greaterthan5 or lessthan1.25 jzg(9).Polio-reactiveAb@was elicitedonlyafterimmunizationofmicewitheither5or0.5 @gof a-Id(7). a-Id forAIDS FunctionsandspecificitiesoftheAb@elicitedbyimmunization Inthecaseof AIDScompleteinactivationoflivinghumanT witha-Id antibodiescannotalwaysbe predictedasshownby cellleukemiavirusIllmaypresentaformidableproblemifwhole theresultsobtainedinmiceimmunizedwithpolyclonalrabbita- virusvaccineswerethe immediategoal.Vaccinesbasedon Id antibodyOneof theanti-rabiesmonoclonalantibodiesused noninfectiousviral components may be in the offing. At the same 1 Presented at the HTLV Symposium, December 6 and 7, 1984, Bethesda, MD. timeproductionofa-Id antibodiesbyimmunizationofanimals This work was supported in part by research grant Al-09706 from the National with purifiedidiotypesobtainedfrom a groupof healthyindivid Institute of Allergy and Infectious Diseases. 2 The abbreviations used are: Id, idiotype; AIDS, acquired immunodeficiency ualswho were exposedto AIDS may be anotheravenueto syndrome. follow.Whenthe a-Idsare produceditis hopedthattheywill CANCERRESEARCHVOL.45 SEPTEMBER1985 4689s Downloaded from cancerres.aacrjournals.org on September 25, 2021. © 1985 American Association for Cancer Research. IMMUNIZATION WITH ANTI-Id ANTIBODY Table1 Immunityofmiceagainstvirusesfollowingimmunizationwithanti-idantibodies Anti-Id anti bodies pro a-IdTobacco Wus duced in ClassCross-reactivityImmunity of miceimmunizedwith mosaic Rabbit interspecies antibodies antibodyRabiesPolyclonalSpecificReoPolyclonal Mouse MonoclonalCross-reactiveCross-reactiveinterspeciesNeutralizing CytotoxicT-cel@'neutralizing antibodyHepatitis Aabbit for monoclonalantibody idi otypesNeutralizing PeptideSandalMouseMonoclona?'Non-H-2BRabbitPolyclonalCross-reactive interspeciesBinding to HepatitisBantigenandto challengeVenezuelan restricted122-137 Cytotoxic T cells; resistanceto antibodytiePolioequine encephalomyeli RabbitPolyclonalCross-reactive interspeciesNeutralizing IIMouseMonoclonalCross-reactiveNeutralizing antibody a @c@teasily generated when hybridoma cells are used for @nmunization. b@@ted by immunization with T-cell receptor specific for Sandal virus. cross-reactwith Id sharedby antibodypreparationsfrommany 1.Syngeneicmonoclonalanti-ldiotypeantibodyidentffiesacellsurfacereceptor for reovirus.J.Immunol.,131:2533—2538,1983. differentindividuals.Thedosagefor effectivevaccinationwitha- 3. ErtI,H.C.,andF@mberg,A.W.SandalvirusspecificTcellclones:inductionof Idswouldhavetobecarefullyinvestigated.Whatremainsunpre cytolyticT cellsby an anti-Idiotypicantibodydirectedagainsta helperTcell done.Proc.Nati.Aced.Sci.USA,81:2850—2854,1984. dictableatpresentisnotonlythespecificitybutalsothefunctions 4. Kennedy,A. C., Dreesman,G. A., Sparrow,J. T., Cuiwell,A. R., Sanchez,V., of Abe,i.e.•whetherthey will ultimatelybeableto stopthe lonescu-Matiu,I.,Holhnger,F.B.,Melnick,J.L Inhibitionofacommonhuman infection. anti-hepatitisBsurfaceantigenidiotypebya cyclicsyntheticpeptide.J.Wol., 46: 653-655, 1983. Whateverthe answer may be efforts to proceedare worth 5. Kennedy,A. C., Sanchez,V., tonescu-Matiu,I.,Melnick,J. L, andDreesman, while,particularlysincetoolsto studythis problemarenow G.A.Acommonhumananti-hepatitisBsurfaceantigenidsOtypeisassociated withthegroupaconformation-dependentantigenicdeterminant.Virology,122: availableandnotimeshouldbelostinstartingtheseinvestiga 219—221,1982. tions. 6. Reagan,K.J.,wunner,w.H.,Wiktor,T.,andKoprowski,H.Anti.idiotypic antibodiesinduceneutralizingantibodiestorabiesvirusglycoproteins.J.Virol., 48: 980-666, 1983. Glossary 7. UydeHaag,F. G. C. M., and Osterhaus,A. D. M. E. Inductionofneutralizing antibodyinmiceagainstpoliovirustypeII withmonoclonalanti-idiotypic Inordertociarifytheterminologyusedinthispublicationthefollowingglossary body. J. Immunol, 134: 1225—1229,1985. is offeredtothereader. 8. Kennedy,A.C.,Sparrow.J.T.,Sanchez,V.,Melnick,J.L, andDreesman, G. A. EnhancementofviralhepatitisBantibody(antl-HBs)responsetoa Epitope: antigenic determinant of moleculesother than @nmunogIobulins. synthetic cyclic peptide by priming with anti-idiotype antibodies. Virology, 136: Idiotope: an antigenic determinant formed by the variable regions of the heavy 247—252,1984. and/or light chains of an antibody molecule. An idlotope that mimics an epltope of 9. Koprowsld,H.,Wsktor,T.J.,Reagan,K.,Mactartan,A.,andDietzschold,B.A a foreign protein is referred to as internal image. newgenerationofrabiesvaccines:rabiesglycoproteingenerecombinants, Abs:antibodies that would be induced by and react with epitopes present on an anti-dotypicantibodiesandsyntheticpeptides.In: ModemApproachesto antigen used for vaccination. Vaccines:MolecularandOnemicalBasisofAeSiStancetoWal, Bacterial,and Abe: antibodies generated in response to and reacting with idiotopes of Ab@. Parasitic Diseases. Proceedingsof meeting in September 1984. Cold Spring This set of antibodies is further subdivided into: Harbor, NY: Cold Spring Harbor Laboratory, in press, 1985. Ab@:antibodies binding to framework-associated idiotopes. 10. RUbinStein,L J., Goldberg,B., Inemaux,J., Stein, K. E., and Bone, C. A. Ab,@:antibodiesbinding to combining-site

View Full Text

Details

  • File Type
    pdf
  • Upload Time
    -
  • Content Languages
    English
  • Upload User
    Anonymous/Not logged-in
  • File Pages
    3 Page
  • File Size
    -

Download

Channel Download Status
Express Download Enable

Copyright

We respect the copyrights and intellectual property rights of all users. All uploaded documents are either original works of the uploader or authorized works of the rightful owners.

  • Not to be reproduced or distributed without explicit permission.
  • Not used for commercial purposes outside of approved use cases.
  • Not used to infringe on the rights of the original creators.
  • If you believe any content infringes your copyright, please contact us immediately.

Support

For help with questions, suggestions, or problems, please contact us